{"id":1009537,"date":"2026-10-13T09:28:24","date_gmt":"2026-10-13T13:28:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/"},"modified":"2026-10-13T09:28:24","modified_gmt":"2026-10-13T13:28:24","slug":"intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/","title":{"rendered":"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Oct.  13, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T2Icv-vVE5usrev_YEvtg9KlAaSwtFBaFddFQ4s5mu0OuvZZjYugiZ_C6Vstx7U3RpsQ3ThRXGiy5dErBrFtrXTUDnqLia3Wdi-704wuIq0=\" rel=\"nofollow\" target=\"_blank\">Intellia Therapeutics, Inc.<\/a> (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company\u2019s translational, development, regulatory and medical affairs functions.<\/p>\n<p>\u201cJing is an exceptional leader with a track record of success in the rare disease space across the full lifecycle from development through regulatory approval and commercialization,\u201d said John Leonard, M.D., Intellia President and Chief Executive Officer. \u201cWe are delighted to welcome her as our Chief Medical Officer during this exciting and momentous time at Intellia. Her unique combination of development and business experience will be critical for our next phase as we seek to commercialize our first potential <em>in vivo<\/em> gene editing product, advance our Phase 3 clinical trials in transthyretin amyloidosis and further expand our pipeline.\u201d<\/p>\n<p>\u201cI am thrilled to join Intellia, where we have the opportunity to profoundly improve patient lives by delivering durable efficacy while minimizing treatment burden leveraging Nobel-prize-winning science,\u201d said Dr. Marantz. \u201cI look forward to working with the company\u2019s talented team to advance our clinical programs with the goal of bringing new therapeutic options to patients with serious diseases.\u201d<\/p>\n<p>Dr. Marantz\u2019s leadership experience spans research and development, medical affairs, business development and portfolio strategy across multiple specialties and rare diseases. Most recently, she served as Chief Medical Officer for Scholar Rock, where she led the development organization in advancing multiple clinical programs across neuromuscular, oncology and obesity, culminating in the U.S. approval of ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy. During her tenure at Scholar Rock, Dr. Marantz led simultaneous regulatory submissions to the U.S. Food and Drug Administration and European Medicines Agency followed by successful engagement with Japan\u2019s Pharmaceuticals and Medical Devices Agency, achieving alignment for a Japanese New Drug Application submission without clinical trial data in Japanese patients.<\/p>\n<p>Prior to her role at Scholar Rock, Dr. Marantz held senior leadership positions at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD and Millennium Pharmaceuticals, playing key roles in the development and commercialization of over a dozen products across hematology\/oncology, neurology and rare diseases. She is a member of the Board of Directors for Arcturus Therapeutics, Inc. Dr. Marantz received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from the Medical University of South Carolina, and an MBA from the University of California at Berkeley.<\/p>\n<p>\n        <strong>About Intellia Therapeutics<\/strong><br \/>\n        <br \/>Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company\u2019s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7-Q1ql0sfZjPCG2aSRSFECeixwkrTQRh2RMpkpCDcOsz26Km5BhPpC92sKNnc6IuB_T0i3CIktRSF_cPt5HAFYkRaFTIg-SNUX6dmi-W0TY=\" rel=\"nofollow\" target=\"_blank\">intelliatx.com<\/a> and follow us <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vn5Yk9ou2sBXTPe039fto3K1AAEC4UM-Mm4S0vetweM7IiRHfY4RRMPfqdOOK5gFcAm8etIw6ymK9iSLwXhcuA==\" rel=\"nofollow\" target=\"_blank\">@intelliatx<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d of Intellia Therapeutics, Inc. (\u201cIntellia\u201d or the \u201cCompany\u201d) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia\u2019s beliefs and expectations concerning: its ability, and the impact of its executive leadership on its ability to commercialize lonvoguran ziclumeran (\u201clonvo-z\u201d), its first potential <em>in vivo<\/em> gene editing product, advance its Phase 3 clinical trials of nexiguran ziclumeran (\u201cnex-z\u201d) in transthyretin amyloidosis and further expand its pipeline.<\/p>\n<p>Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z and nex-z, including risks related to the ability to develop and successfully commercialize lonvo-z, nex-z or any of Intellia\u2019s product candidates; risks related to Intellia\u2019s ability to protect and maintain its intellectual property position; risks related to Intellia\u2019s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials or regulatory filings due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia\u2019s actual results to differ from those contained in the forward-looking statements, see the section entitled \u201cRisk Factors\u201d in Intellia\u2019s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia\u2019s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.<\/p>\n<p>\n        <strong><br \/>\n          <em>Investor Contact:<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Jason Fredette<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Intellia Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aWZKuhh6eCWc2iQ6n90xCoiPO_UTK4BQceUFc9g4FDOVo4dTSGQ_E6KU6Ob4evHSTQrnRGXqmOk8a2Qm9UBa_LJVq758KPDnhkb9McOlSFzx4nCcFvd6-tb449IPpJHI\" rel=\"nofollow\" target=\"_blank\">jason.fredette@intelliatx.com<\/a><\/p>\n<p>\n        <strong><br \/>\n          <em>Media\u00a0Contact:<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Mike Tattory<br \/>Vice President<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=irbcytBVdwH9aT_FmPX9zYIQWi7MCxvuO5vZqQWIVGtW15yqHHe2pzn62GZfxqRjmQrcFuHC4tsKLvGRprxxWBWgXU0IvKvnq4lMiYTI6zfPgsTn3xUBEIYdfvXCJeBM\" rel=\"nofollow\" target=\"_blank\">mtattory@lifescicomms.com<\/a><\/p>\n<p>This press release was published by a CLEAR\u00ae Verified individual.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTQxZDY0MGEtNGVmMy00OWRiLTlkYWMtZDZmNDljZjc5OTY1LTEwNDA3NzItMjAyNi0xMC0xMy1lbg==\/tiny\/Intellia-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company\u2019s translational, development, regulatory and medical affairs functions. \u201cJing is an exceptional leader with a track record of success in the rare disease space across the full lifecycle from development through &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1009537","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company\u2019s translational, development, regulatory and medical affairs functions. \u201cJing is an exceptional leader with a track record of success in the rare disease space across the full lifecycle from development through &hellip; Continue reading &quot;Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-13T13:28:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer\",\"datePublished\":\"2026-10-13T13:28:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/\"},\"wordCount\":985,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/\",\"name\":\"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=\",\"datePublished\":\"2026-10-13T13:28:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company\u2019s translational, development, regulatory and medical affairs functions. \u201cJing is an exceptional leader with a track record of success in the rare disease space across the full lifecycle from development through &hellip; Continue reading \"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-13T13:28:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer","datePublished":"2026-10-13T13:28:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/"},"wordCount":985,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/","name":"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=","datePublished":"2026-10-13T13:28:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MzI3MCM3ODg4ODkxIzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-appoints-jing-l-marantz-m-d-ph-d-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009537","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1009537"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1009537\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1009537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1009537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1009537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}